














We claim:

1. A composition comprising a CD47-SIRP α blocking agent and one or more anti-cancer agent(s); wherein the CD47-SIRP α blocking agent is selected from the group consisting of:

Compound	Structure
1	
2	
3	
4	
5	
6	

Compound	Structure
7	
8	
9	
10	
11	
12	

Compound	Structure
13	
14	
15	
16	
17	
18	
19	

Compound	Structure
20	
21	
22	
23	
24	
25	
26	

Compound	Structure
27	

or a pharmaceutically acceptable salt or an amide or an ester or a stereoisomer thereof.

2. The composition of claim 1, wherein the anti-cancer agent is a chemotherapeutic agent or an immunomodulatory agent.
3. The composition of claim 2, wherein the chemotherapeutic agent is azacitidine or a
5 proteasome inhibitor (bortezomib, ixazomib and carfilzomib).
4. The composition of claim 2, wherein the immunomodulatory agent is a costimulatory molecule or a coinhibitory molecule comprising antibodies to PD-1 and PD-L1 (e.g., nivolumab, pembrolizumab, atezolizumab, Durvalumab and Camrelizumab).
5. The composition of claim 1, wherein the anticancer agent is a therapeutic antibody
10 targeting tumor antigens that stimulate activating Fc receptors (FcRs).
6. The composition of claim 5, wherein the therapeutic antibody is selected from the group capable of triggering efficient phagocytosis comprising anti CD-20 (rituximab, tiuxetan, and tositumomab).
7. A pharmaceutical composition comprising the CD47-SIRP α blocking agent and one
15 or more anti-cancer agent(s) as claimed in claim 1, and a pharmaceutically acceptable carrier.
8. Use of a therapeutically effective amount of the composition of claim 1 in the manufacture of a medicament for treating or delaying progression of diseases or disorders mediated by deregulated CD47-SIRP α pathway in a subject.
9. The use of claim 8, wherein the subject presenting a dysregulated CD47 pathway is a
20 subject presenting with CD47⁺ disease cells.
10. The use of claim 8, wherein the disease or disorder is cancer mediated by dysregulated CD47-SIRP α pathway.

11. The use of claim 10, wherein the cancer is selected from melanoma, renal cancer, prostate cancer, breast cancer, colon cancer and lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumours of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), non-small cell lung cancer (NSCLC), primary CNS lymphoma, tumour angiogenesis, spinal axis tumour, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, B-cell lymphomas, myeloproliferative disorder/neoplasm (MPDS); myelodysplastic syndrome; giant cell myeloma, heavy-chain myeloma, light chain myeloma and Bence- Jones myeloma, multiple myeloma, environmentally induced cancers including those induced by asbestos (e.g., mesothelioma), and combinations of said cancers.
12. The composition of claim 1, for use as a medicament.
13. The composition of claim 1, for use in treating or delaying progression of diseases or disorders mediated by deregulated CD47-SIRP α pathway in a subject.
14. The composition for use of claim 13, wherein the subject presenting a dysregulated CD47 pathway is a subject presenting with CD47⁺ disease cells.
15. The composition for use of claim 13, wherein the disease or disorder is cancer mediated by dysregulated CD47-SIRP α pathway.
16. The composition for use of claim 15, wherein the cancer is selected from melanoma, renal cancer, prostate cancer, breast cancer, colon cancer and lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease,

non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumours of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), non-small cell lung cancer (NSCLC), primary CNS lymphoma, tumour angiogenesis, spinal axis tumour, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, B-cell lymphomas, myeloproliferative disorder/neoplasm (MPDS); myelodysplastic syndrome; giant cell myeloma, heavy-chain myeloma, light chain myeloma and Bence- Jones myeloma, multiple myeloma, environmentally induced cancers including those induced by asbestos (e.g., mesothelioma), and combinations of said cancers.